Skip to search formSkip to main contentSkip to account menu

tasidotin

A third generation, synthetic, water-soluble, pentapeptide analog of the marine depsipeptide dolastatin 15, with potential antimitotic and… 
National Institutes of Health

Related topics

Related topics

5 relations

Narrower (2)

ILX 651tasidotin hydrochloride
Microtubule ProcessNCIt Antineoplastic Agent Terminology

Broader (1)

Oligopeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2015
Review
2015
Anticancer compounds from cyanobacterium Lyngbya species: a review
The use of synthetic anticancer drugs and other methods followed in cancer therapy have several side effects; and ineffective… 
2013
2013
Mechanism of mitotic arrest induced by dolastatin 15 involves loss of tension across kinetochore pairs
Dolastatin 15 (DL15) is a potent, tubulin-targeted, vinca-site binding, anticancer agent that induces mitotic arrest and inhibit… 
2009
2009
Bone marrow CFU-GM and human tumor xenograft efficacy of three tubulin binding agents
PurposeThe dynamic instability of microtubules in cells is one of the key targets of anticancer therapeutics. Microtubule… 
2009
2009
Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
PurposeTo evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in… 
Highly Cited
2007
Highly Cited
2007
Mechanism of action of the microtubule-targeted antimitotic depsipeptide tasidotin (formerly ILX651) and its major metabolite tasidotin C-carboxylate.
Tasidotin (ILX-651), an orally active synthetic microtubule-targeted derivative of the marine depsipeptide dolastatin-15, is… 
2005
2005
A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose, dose-limiting toxicity, and pharmacokinetics of the dolastatin-15 analogue… 
2005
2005
Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Purpose: To determine the maximum tolerated dose (MTD), dose-limiting toxicity (DLT), and pharmacokinetics of tasidotin (ILX651… 
Review
2005
Review
2005
Tasidotin HCl (Genzyme).
2005
2005
Plaunotol inhibits gastric cancer cells by induction of apoptosis
5903 BACKGROUND AND AIM: Plaunotol, a kind of isoprenoid, is an anti-gastric ulcer agent, available for clinical use since more… 
2005
2005
APhase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3Weeks in Patientswith Advanced SolidTumors
Purpose:To determine themaximum tolerated dose, dose-limiting toxicity, andpharmacokinetics of the dolastatin-15 analogue… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)